UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era

Lodi, S; Phillips, A; Touloumi, G; Pantazis, N; Bucher, HC; Babiker, A; Chene, G; ... Collaboration, C; + view all (2010) CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era. AIDS , 24 (17) 2697 - 2704. 10.1097/QAD.0b013e32833ef6c4.

Full text not available from this repository.

Abstract

Background: Studies based on seroconverters have increased our understanding of HIV disease. It is not clear, however, whether their disease progression differs from that of the general HIV population, given their reasons for presenting for testing.Methods: Using linear mixed models we compared CD4 decline rates for a seroconverter (CASCADE) and seroprevalent group (Concorde trial) with time origin being dates of seroconversion and randomization, respectively. Follow-up was censored at the earlier of last alive date and 1 January 1996. Analyses were adjusted for risk group, age and sex. To explore the role of symptomatic seroconversion we further categorized seroconverters into two groups: with and without an HIV test interval below 30 days as proxy.Results: The 7226 seroconverter and 1746 seroprevalent eligible individuals were mainly men (78 and 85%, respectively) infected through sex between men (52 and 63%) with mean [95% confidence interval (CI)] baseline CD4 cell count of 610 (602, 619) and 492 (479, 505) cells/mu l, respectively. There was no evidence that rate of CD4 decline differs between the two groups even after adjusting for potential confounders (P = 0.67). Estimated loss in the year after reaching an arbitrary threshold of 400 cells/ml was 67 (95% CI 65, 69) and 67 (64, 69) cells/mu l in the seroconverter and seroprevalent group, respectively. Whereas seroconverters with test interval below 30 days (n = 310) experienced faster decline, there was no difference in rates between other seroconverters and seroprevalent individuals (P = 0.87).Conclusions: These data suggest that estimates of HIV progression derived from seroconverters are likely to hold more generally for the HIV-infected population. (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins

Type: Article
Title: CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era
DOI: 10.1097/QAD.0b013e32833ef6c4
Keywords: CD4 decline, HIV, natural history, repeat testing, seroconverters, seroprevalent, HIV TEST INTERVAL, DISEASE PROGRESSION, INFECTION, AIDS, COHORT, HAART, DIAGNOSIS, ILLNESS, ADULTS, DEATH
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Pop Health Sciences > Inst of Clinical Trials and Methodology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Pop Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Pop Health Sciences > Institute for Global Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Pop Health Sciences > Institute for Global Health > Infection and Population Health
URI: http://discovery.ucl.ac.uk/id/eprint/706038
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item